SAN FRANCISCO, CA — (January 22, 2021) – Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today announces that its previously announced cease trade order has been revoked.
On June 22, 2020, the British Columbia Securities Commission (the “BCSC”) and the Ontario Securities Commission (the“OSC”) issued a Failure-to-File Cease Trade Order against the Company (the “FFCTO“) due to the Company’s failure to file by the prescribed filing deadlines its annual financial statements for the year ending December 31, 2019, and the accompanying Management’s Discussion and Analysis and certifications. As a result, the TSXV also suspended trading of the Company’s common shares. The Company’s auditor, BDO, has now completed the audit of the Company’s financial statements for the year ended December 31, 2019, and the Company has now filed the audited financial statements for 2019, the quarterly financial statements for Q1 2020 (for period ending in March 31, 2020), Q2 2020 (for period ending in June 30, 2020) and Q3 2020 (for period ending in September 30, 2020) , and the accompanying Management’s Discussion and Analysis and certifications for all three periods (the “Filings”). The Company applied to the BCSC and the OSC on November 4, 2020 to have the FFCTO fully revoked, and has applied to the TSXV on October 30, 2020 to have the Company’s shares resume trading after the FFCTO has been fully revoked. The BCSC and the OSC granted the full revocation with respect of the FFCTO on January 22, 2021. The Company is following up with the TSXV to remove its suspension and resume the trading of the Company’s common shares, which resumption when effected will be confirmed in a follow up press release.
The Company confirms that its business has not changed, the Company remains active, and there are no changes to its current business plans.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
- Website Home: https://kalytera.co/
- News and Insights: https://kalytera.co/news/
- Investors: https://kalytera.co/investors/
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, in particular with respect of any implications the removal of the FFCTO and the resumption of trading of the securities of the Company may have. The impact of the resumption of such trading (if any) is unknown and Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
- Robert Farrell